Solid Tumor Antigens

Solid tumor antigen antibodies bind surface proteins overexpressed on carcinoma, sarcoma or neuroblastoma cells. Zolbetuximab targets claudin 18.2, and enfortumab binds Nectin-4, an adhesion protein that is common in urothelial cancer. Sacituzumab and datopotamab bind trophoblast cell-surface antigen 2 (TROP2), and mirvetuximab binds folate receptor alpha (FRα). Dinutuximab recognizes the disialoganglioside GD2, and labetuzumab binds carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Many of these antibodies are the targeting component of antibody-drug conjugates used in internalization, payload delivery and cytotoxicity studies.

5 Items

  • Lexatumumab — antibody illustration
    Cat. No.
    AT0457

    Lexatumumab

    Synonyms: HGS-ETR 2; ETR2-ST01

    Lexatumumab (HGS-ETR 2) is a human monoclonal antibody of the IgG4Īŗ subtype that functions as an agonist to TRAIL receptor 2 (TRAIL-R2, also known as DR5 or APO-2). This antibody is specifically designed to induce apoptosis in cells exhibiting malignant mesothelioma characteristics. It is primarily utilized in research focused on understanding and treating malignant pleural mesothelioma (MPM), offering significant value in studies aimed at exploring targeted cancer therapies.

    1 mg
    $208.00
    5 mg
    $624.00
    All 3 sizes
  • Drozitumab — antibody illustration
    Cat. No.
    AT0622

    Drozitumab

    Synonyms: PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody

    Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.

    1 mg
    $240.00
    5 mg
    $720.00
    All 3 sizes
  • Benufutamab — antibody illustration
    Cat. No.
    AT0737

    Benufutamab

    Synonyms: GEN1029

    Benufutamab (GEN1029) is an agonistic antibody targeting death receptor 5 (DR5), designed to selectively initiate apoptosis in tumor cells. This biologic is composed of two non-competing, DR5-specific IgG1 antibodies, each engineered with an E430G mutation in the Fc domain to enhance its therapeutic efficacy. Benufutamab demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy and apoptosis mechanisms.

    1 mg
    $400.00
    5 mg
    $1,200.00
    All 3 sizes
  • Tilogotamab — antibody illustration
    Cat. No.
    AT1303

    Tilogotamab

    Synonyms: HexaBody-DR5/DR5; Hx-DR5-01/05

    Tilogotamab is an enhanced agonistic formulation composed of two antibodies, each targeting distinct epitopes on death receptor type 5 (DR5). This specific interaction with DR5 facilitates its activation, making Tilogotamab a valuable tool in the study of multiple myeloma (MM). This product is designed for research use, focusing on elucidating the pathways and mechanisms associated with DR5 in multiple myeloma.

    1 mg
    $240.00
    5 mg
    $720.00
    All 3 sizes
  • Conatumumab — antibody illustration
    Cat. No.
    AT1457

    Conatumumab

    Synonyms: AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

    Conatumumab (AMG 655) is a human monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2), displaying high affinity with dissociation constants (Kd) of 1 nM for the long form of DR5 and 0.8 nM for the short form. This antibody functions by inducing apoptosis through caspase activation, making it highly relevant for cancer research applications.

    1 mg
    $368.00
    5 mg
    $920.00
    All 3 sizes

5 Items

Added to your cart

View Cart Checkout

    Loading...